Any company that creates products and relies on other companies to use and distribute them will inevitably forge strong relationships with its customers. It's an important thing to look into when investing, yet easy to overlook. Investors should know whether customers are reliable, which are leaned on the most, and if the company they own is too dependent on any customer (or a select few). Bioprocessing product company Repligen (NASDAQ: RGEN ) may make consumables that are the lifeline of the biotech industry, but its customer relationships are absolutely critical for smooth operations. Let's look at how the company interacts with the Life Sciences division of General Electric (NYSE: GE ) , EMD Millipore from Merck (NYSE: MRK ) , and Sigma-Aldrich (NASDAQ: SIAL ) -- the three most important customers.
Source: Repligen Stephens Fall Investment Conference.
Top 10 Valued Companies To Invest In Right Now: Syneron Medical Ltd. (ELOS)
Syneron Medical Ltd., together with its subsidiaries, engages in the research, manufacture, development, marketing, and sale of aesthetic medical products worldwide. The company develops products based on its proprietary Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy and optical energy to provide aesthetic medical treatments. Its products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin�s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, laser-assisted lipolysis, and topical skin brightening products. It also develops, manufactures, and markets non-invasive technologies for fat cell destruction and body sculpting; and Viador system, a handheld device with a radiofrequency-needle array for use in transdermal delivery of biologic drug-products via a system-specific skin patch. The company sells its products to dermatologists, plastic and cosmetic surgeons, other qualified practitioners, and aestheticians and medical spas through direct sales force and distributors; and to home-use consumers directly, as well as through retailers and a chain of distributors. Syneron Medical Ltd. was founded in 2000 and is headquartered in Yokneam Illit, Israel.
Advisors' Opinion:- [By John Udovich]
Large cap serial acquirer�Valeant Pharmaceuticals International Inc (NYSE: VRX) is teaming up with activist investor�Bill Ackman to pursue large cap Botox maker Allergan, Inc (NYSE: AGN), but stocks like Cutera, Inc (NASDAQ: CUTR), Cynosure, Inc (NASDAQ: CYNO), PhotoMedex Inc (NASDAQ: PHMD) and Syneron Medical Ltd (NASDAQ: ELOS)�actually offer investors more exposure to the growing anti aging and aesthetics market (Note: See my recent article: These Small Caps Seek to Treat Your Crow�� Feet and Double Chin (RVNC & KYTH)). To begin with, Valeant Pharmaceuticals International has a wide focus on neurology, dermatology and infectious diseases�but acquiring the maker of Botox won�� be its first foray into the aesthetic market�because earlier this year, the company completed its acquisition of Solta Medical Inc (NASDAQ: SLTM) -�a designer, developer, manufacturer and marketer of�energy-based medical device systems for aesthetic applications.�And while�Allergan, Inc may be most well known for Botox, its actually a pretty big�company focused on a diverse range of areas, including ophthalmic pharmaceuticals, dermatology, neuroscience, urology and cosmetics���meaning the following stocks offer investors better exposure to the aesthetics market:
Top 5 Life Sciences Stocks To Watch For 2015: Electro Rent Corporation(ELRC)
Electro Rent Corporation engages in the rental, lease, and sale of new and used electronic test and measurement equipment. Its equipment portfolio consists of general purpose test and measurement instruments; personal computers, workstations, and servers; and electrical test equipment and inspection equipment. The company rents or leases its equipment primarily to companies operating in the aerospace, defense, telecommunications, electronics, and semiconductor industries. Electro Rent Corporation serves its customers through sales offices, and calibration and service centers in the United States, Canada, China, and Europe. The company was founded in 1965 and is headquartered in Van Nuys, California.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Electro Rent (Nasdaq: ELRC ) , whose recent revenue and earnings are plotted below. - [By Lisa Levin]
Electro Rent (NASDAQ: ELRC) shares fell 0.77% to reach a new 52-week low of $15.39. Electro Rent's trailing-twelve-month profit margin is 9.24%.
Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets
Top 5 Life Sciences Stocks To Watch For 2015: OncoMed Pharmaceuticals Inc (OMED)
OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company's anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.
Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.
Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.
The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-bas! ed therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
OncoMed Pharmaceuticals (NASDAQ: OMED) shot up 8.62 percent to $30.09 after the company initiated Phase 1B trial of WNT-parthway-target antibody. Jefferies lifted the price target on the stock from $27 to $46.
Top 5 Life Sciences Stocks To Watch For 2015: Liquidmetal Technologies Inc (LQMT)
Liquidmetal Technologies, Inc. (Liquidmetal Technologies), incorporated in 1987, is materials technology company that develops and commercializes products made from amorphous alloys. The Company's Liquidmetal family of alloys consists of a variety of bulk alloys and composites that utilize the advantages offered by amorphous alloy technology. The Company designs develop and sell products and components from bulk amorphous alloys to customers in various industries. The Company also partners with third-party manufacturers and licensees to develop and commercialize Liquidmetal alloy products. The Company focused to commercializes its Liquidmetal alloys on three identified product areas, such as Components for Non-Consumer Electronic Products, Sporting Goods and Leisure Products and Medical Devices. On December 1, 2011, the Company entered into a Share Purchase Agreement with LMTK Holdings, Inc. (LMTK Holdings) to sell its former Korean subsidiary and manufacturing facility, Liquidmetal Technologies Korea (LMTK). Under the Share Purchase Agreement, the Company sold all of LMTK�� shares of common stock to LMTK Holdings.
The Company designs, develops and produces components for non-consumer electronic devices utilizing its bulk Liquidmetal alloys. The product categories in the non-consumer electronics field include, but are not limited to, parts for high end printers, commercial imaging devices, aerospace components, medical devices and industrial machines. The Company is also developing a variety of applications for Liquidmetal alloys in the sporting goods and leisure products area.
The Company develops a variety of applications for Liquidmetal alloys in the sporting goods and leisure products area. In the sporting goods industry the Company focuses on products that meet its design criteria. The Company has produced prototype rings made from an amorphous Liquidmetal platinum alloy that is harder, in the leisure products category. The Company emphasis on surgical instrument appl! ications for Liquidmetal alloys. These include, but are not limited to, specialized blades, orthopedic instruments utilized for implant surgery procedures, dental devices and general surgery devices
The Company is engaged in product development efforts relating to various medical devices that could be made from bulk Liquidmetal alloys. The properties of bulk Liquidmetal alloys provide a combination of performance that makes them a replacement to incumbent materials, such as stainless steel and titanium.
Advisors' Opinion:- [By Bryan Murphy]
With just a quick glance at its chart, Liquidmetal Technologies Inc. (OTCBB:LQMT) looks like little more than a tangled, indecisive mess. As you take a longer look at LQMT chart though, a modest bullish hint starts to appear. This may be one of the budding superstar stocks for Q4.
- [By John Udovich]
On Wednesday, small cap Liquidmetal Technologies Inc (OTCBB: LQMT) spiked 223.2% on renewed speculation about Apple (NASDAQ: AAPL) having won a patent for a process to mass produce Liquidmetal, but what�� the whole story for investors?
- [By James E. Brumley]
Well, I hate to be the one to say I told you so, but, I told you so. Back on November 22nd I told you the gain from Liquidmetal Technologies Inc. (OTCBB:LQMT) was no ordinary gain. It was a catalyst for a much bigger bullish move. See, with that day's advance, LQMT hopped above a nagging resistance line. The end result was a stock that was not only proverbially free to move about the cabin, but a stock that had proven it had already established some upward momentum. Sure enough, Liquidmetal Technologies shares are up 47% since then. You're welcome.
- [By CRWE]
Today, LQMT�has shed (-6.60%) down -0.01 at $.13 with 950,168 shares in play thus far (ref. google finance Delayed: 1:45PM�EDT October 14, 2013).
Liquidmetal Technologies previously reported delivery of its customized induction melt system, developed to adapt standard plastic injection molding machines to manufacture Liquidmetal components.
After extensive revisions and trials with the current Liquidmetal system, Liquidmetal Technologies and Engel Austria GmbH (Engel), a Certified Liquidmetal Partner, have agreed to a configuration that can be commercially supplied and supported by Engel. The Liquidmetal-designed system has been shipped to Engel to be installed as part of a standard injection-molding machine.
No comments:
Post a Comment